This site requires JavaScript to render the code.

Need to know how to enable JavaScript? Go here.


Long term CIN3+ risk of HPV positive women after triage with FAM19A4/mir124-2, methylation analysis.
Dick et al, Gynaecological oncology 2019 Jun 7, S0090-8258(19)31279-X.


Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.
De Strooper et al. Gynecol Oncology, vol 141(2), pp341-347, 2016.


Clinical validation of the HPV-Risk Assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
Hesselink et al. J Clin Microbiol. 2014;52(3):890-896.


Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Overmeer et al. Int J Cancer. 2011;129:2218-25.


Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
Polman et al, J Clin Microbiol. 2017 Dec;55(12):3544-3551.


Management of high-risk HPV-positive women for detection of cervical (pre)cancer.
Luttmer et al Expert Rev Mol Diagn. 2016 Sep;16(9):961-74.